-
Process
- Our New Model
- RF Biocidics
- SoundCure
- CryoXtract
-
Form
We identify the most promising early-stage laboratory research -- breakthroughs with the potential to have a significant impact on commercial markets. If an emerging technology passes our due diligence, we form a subsidiary company that gives the inventors and their institutions a stake in its success.
Fund
Our model for funding innovation is unique. Unlike typical venture-backed startups, our subsidiaries are wholly funded by a single parent company, Allied Minds. Each venture becomes part of our network for sharing expertise and resources.
Manage
We staff our subsidiaries with a talented team that knows how to create world-class products. Leading each venture is a seasoned director who manages each stage of the product development cycle, from prototyping and manufacturing to legal and regulatory to tests and trials.
Build
Finally, we build enterprises that bring innovations to market. Once a venture is generating revenue and profits, we enable the next level of success, which could result in a liquidity event such as an IPO or acquisition.
-
Form
Allied Minds formed RF Biocidics to commercialize a method of using radio frequency waves to disinfect food, water and other products—a safe, low-cost solution for a multi-billion dollar market. The technology is based on a decade of research by a University of California-Davis scientist who receives an equity stake in the startup.
Fund
RF Biocidics received seed funding in 2008, and three years later, it is funded by a $10 million private equity investment raised by Allied Minds. The capital goes toward the design of a line of commercial products aimed at foothold markets such as disinfecting massive volumes of almond, cashews and other nuts.
Manage
As managing director of RF Biocidics, Fortunato Villamanga brings 25 years of experience leading scientific companies in related markets. His team manages the commercialization process while extending the core technology to dozens of additional disinfection applications.
Build
As RF Biocidics expands beyond its initial foothold markets, Fortunato and his team are building a mass manufacturing capability and scaling up the enterprise. The company has recorded sales in the millions within three years of taking the idea from academic research.
-
Form
Allied Minds forms SoundCure to commercialize a breakthrough acoustic device for treating tinnitus. This “ringing in the ear” syndrome afflicts about 17% of the adult population and it is the #1 disability affecting military servicemen and women returning from the field. Key researchers at the University of California-Irvine received an equity stake in the new enterprise.
Fund
SoundCure raised seed funding in 2009. Eighteen months later, it received a $3 million Series A investment to design and develop a consumer-ready product. The funding takes the novel device through consumer trials and the FDA approval process.
Manage
As SoundCure’s managing director, Bill Perry leverages his 20 years of experience leading venture capital-backed medical device companies. His team manages all stages of the go-to-market strategy, including engineering, sales, marketing and business development.
Build
The commercial launch of its tinnitus treatment device in late 2011, will set the stage for significant growth at SoundCure. As sales ramp up, Bill and his team are executing a strategic plan for capitalizing on a multi-billion dollar opportunity.
SoundCure represents the second spinout from the University of California system.
-
Form
Biological samples are critical resources in biomedical research projects and improper handling such as repeated freeze-thaw cycles will compromise important studies. Harvard University, Northeastern University and Allied Minds formed CryoXtract to develop and commercialize a unique robotic technology designed to extract multiple, uniform frozen aliquots from a frozen sample without exposing it to a thaw cycle. The universities receive membership stake in the new enterprise and key researchers are given options in the enterprise.
Fund
CryoXtract received seed funding in 2008. In 2011, it raised a $3 million Series A investment to support commercialization of its proprietary Automated Frozen Sample Aliquotter. The funding helped launch CryoXtract’s first application of this unique robotic solution.
Manage
In 2010, Allied Minds named Jorge de Dios as CEO of CryoXtract. With over 20 years of corporate strategy experience at Fortune 500 companies, Jorge’s team manages all stages of the go-to-market strategy, including engineering, manufacturing, business development and sales and marketing, and R&D.
Build
The commercial launch of its Automated Frozen Sample Aliquotter, planned for 2012, will set the stage for significant growth at CryoXtract. Jorge and the CryoXtract team are executing a strategic plan to capitalize on a multi-million dollar opportunity by extending the core technology into new product platforms and applications.
CryoXtract is one of three spinouts from Harvard University.
